La FDA approuve la variation d’AMM de Somatuline® Depot (lanréotide) Injection d’Ipsen : allongement de l’intervalle posologique

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021